Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population

Neil J. Weissman, Robert L. Wilensky, Jean Francois Tanguay, Antonio L. Bartorelli, Jeffery Moses, David O. Williams, Steven Bailey, Jack L. Martin, Michael R. Canos, Harish Rudra, Jeffrey J. Popma, Martin B. Leon, Aaron V. Kaplan, Gary S. Mintz

Research output: Contribution to journalArticle

Abstract

Intimal hyperplasia within the body of the stent is the primary mechanism for in-stent restenosis; however, stent edge restenosis has been described after brachytherapy. Our current understanding about the magnitude of in vivo intimal hyperplasia and edge restenosis is limited to data obtained primarily from select, symptomatic patients requiring repeat angiography. The purpose of this study was to determine the extent and distribution of intimal hyperplasia both within the stent and along the stent edge in relatively nonselect, asymptomatic patients scheduled for 6-month intravascular ultrasound (IVUS) as part of a multicenter trial: Heparin Infusion Prior to Stenting. Planar IVUS measurements 1 mm apart were obtained throughout the stent and over a length of 10 mm proximal and distal to the stent at index and follow-up. Of the 179 patients enrolled, 140 returned for repeat angiography and IVUS at 6.4 ± 1.9 months and had IVUS images adequate for analysis. Patients had 1.2 ± 0.6 Palmaz-Schatz stents per vessel. There was a wide individual variation of intimal hyperplasia distribution within the stent and no mean predilection for any location. At 6 months, intimal hyperplasia occupied 29.3 ± 16.2% of the stent volume on average. Lumen loss within 2 mm of the stent edge was due primarily to intimal proliferation. Beyond 2 mm, negative remodeling contributed more to lumen loss. Gender, age, vessel location, index plaque burden, hypercholesterolemia, diabetes, and tobacco did not predict luminal narrowing at the stent edges, but diabetes, unstable angina at presentation, and lesion length were predictive of in-stent intimal hyperplasia. In a non-radiation stent population, 29% of the stent volume is filled with intimal hyperplasia at 6 months. Lumen loss at the stent edge is due primarily to intimal proliferation.

Original languageEnglish
Pages (from-to)248-252
Number of pages5
JournalThe American Journal of Cardiology
Volume88
Issue number3
DOIs
Publication statusPublished - Aug 1 2001

Fingerprint

Tunica Intima
Hyperplasia
Stents
Population
Angiography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. / Weissman, Neil J.; Wilensky, Robert L.; Tanguay, Jean Francois; Bartorelli, Antonio L.; Moses, Jeffery; Williams, David O.; Bailey, Steven; Martin, Jack L.; Canos, Michael R.; Rudra, Harish; Popma, Jeffrey J.; Leon, Martin B.; Kaplan, Aaron V.; Mintz, Gary S.

In: The American Journal of Cardiology, Vol. 88, No. 3, 01.08.2001, p. 248-252.

Research output: Contribution to journalArticle

Weissman, NJ, Wilensky, RL, Tanguay, JF, Bartorelli, AL, Moses, J, Williams, DO, Bailey, S, Martin, JL, Canos, MR, Rudra, H, Popma, JJ, Leon, MB, Kaplan, AV & Mintz, GS 2001, 'Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population', The American Journal of Cardiology, vol. 88, no. 3, pp. 248-252. https://doi.org/10.1016/S0002-9149(01)01635-6
Weissman, Neil J. ; Wilensky, Robert L. ; Tanguay, Jean Francois ; Bartorelli, Antonio L. ; Moses, Jeffery ; Williams, David O. ; Bailey, Steven ; Martin, Jack L. ; Canos, Michael R. ; Rudra, Harish ; Popma, Jeffrey J. ; Leon, Martin B. ; Kaplan, Aaron V. ; Mintz, Gary S. / Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. In: The American Journal of Cardiology. 2001 ; Vol. 88, No. 3. pp. 248-252.
@article{86f08bf8527f4a95ae5516e50bca03a4,
title = "Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population",
abstract = "Intimal hyperplasia within the body of the stent is the primary mechanism for in-stent restenosis; however, stent edge restenosis has been described after brachytherapy. Our current understanding about the magnitude of in vivo intimal hyperplasia and edge restenosis is limited to data obtained primarily from select, symptomatic patients requiring repeat angiography. The purpose of this study was to determine the extent and distribution of intimal hyperplasia both within the stent and along the stent edge in relatively nonselect, asymptomatic patients scheduled for 6-month intravascular ultrasound (IVUS) as part of a multicenter trial: Heparin Infusion Prior to Stenting. Planar IVUS measurements 1 mm apart were obtained throughout the stent and over a length of 10 mm proximal and distal to the stent at index and follow-up. Of the 179 patients enrolled, 140 returned for repeat angiography and IVUS at 6.4 ± 1.9 months and had IVUS images adequate for analysis. Patients had 1.2 ± 0.6 Palmaz-Schatz stents per vessel. There was a wide individual variation of intimal hyperplasia distribution within the stent and no mean predilection for any location. At 6 months, intimal hyperplasia occupied 29.3 ± 16.2{\%} of the stent volume on average. Lumen loss within 2 mm of the stent edge was due primarily to intimal proliferation. Beyond 2 mm, negative remodeling contributed more to lumen loss. Gender, age, vessel location, index plaque burden, hypercholesterolemia, diabetes, and tobacco did not predict luminal narrowing at the stent edges, but diabetes, unstable angina at presentation, and lesion length were predictive of in-stent intimal hyperplasia. In a non-radiation stent population, 29{\%} of the stent volume is filled with intimal hyperplasia at 6 months. Lumen loss at the stent edge is due primarily to intimal proliferation.",
author = "Weissman, {Neil J.} and Wilensky, {Robert L.} and Tanguay, {Jean Francois} and Bartorelli, {Antonio L.} and Jeffery Moses and Williams, {David O.} and Steven Bailey and Martin, {Jack L.} and Canos, {Michael R.} and Harish Rudra and Popma, {Jeffrey J.} and Leon, {Martin B.} and Kaplan, {Aaron V.} and Mintz, {Gary S.}",
year = "2001",
month = "8",
day = "1",
doi = "10.1016/S0002-9149(01)01635-6",
language = "English",
volume = "88",
pages = "248--252",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population

AU - Weissman, Neil J.

AU - Wilensky, Robert L.

AU - Tanguay, Jean Francois

AU - Bartorelli, Antonio L.

AU - Moses, Jeffery

AU - Williams, David O.

AU - Bailey, Steven

AU - Martin, Jack L.

AU - Canos, Michael R.

AU - Rudra, Harish

AU - Popma, Jeffrey J.

AU - Leon, Martin B.

AU - Kaplan, Aaron V.

AU - Mintz, Gary S.

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Intimal hyperplasia within the body of the stent is the primary mechanism for in-stent restenosis; however, stent edge restenosis has been described after brachytherapy. Our current understanding about the magnitude of in vivo intimal hyperplasia and edge restenosis is limited to data obtained primarily from select, symptomatic patients requiring repeat angiography. The purpose of this study was to determine the extent and distribution of intimal hyperplasia both within the stent and along the stent edge in relatively nonselect, asymptomatic patients scheduled for 6-month intravascular ultrasound (IVUS) as part of a multicenter trial: Heparin Infusion Prior to Stenting. Planar IVUS measurements 1 mm apart were obtained throughout the stent and over a length of 10 mm proximal and distal to the stent at index and follow-up. Of the 179 patients enrolled, 140 returned for repeat angiography and IVUS at 6.4 ± 1.9 months and had IVUS images adequate for analysis. Patients had 1.2 ± 0.6 Palmaz-Schatz stents per vessel. There was a wide individual variation of intimal hyperplasia distribution within the stent and no mean predilection for any location. At 6 months, intimal hyperplasia occupied 29.3 ± 16.2% of the stent volume on average. Lumen loss within 2 mm of the stent edge was due primarily to intimal proliferation. Beyond 2 mm, negative remodeling contributed more to lumen loss. Gender, age, vessel location, index plaque burden, hypercholesterolemia, diabetes, and tobacco did not predict luminal narrowing at the stent edges, but diabetes, unstable angina at presentation, and lesion length were predictive of in-stent intimal hyperplasia. In a non-radiation stent population, 29% of the stent volume is filled with intimal hyperplasia at 6 months. Lumen loss at the stent edge is due primarily to intimal proliferation.

AB - Intimal hyperplasia within the body of the stent is the primary mechanism for in-stent restenosis; however, stent edge restenosis has been described after brachytherapy. Our current understanding about the magnitude of in vivo intimal hyperplasia and edge restenosis is limited to data obtained primarily from select, symptomatic patients requiring repeat angiography. The purpose of this study was to determine the extent and distribution of intimal hyperplasia both within the stent and along the stent edge in relatively nonselect, asymptomatic patients scheduled for 6-month intravascular ultrasound (IVUS) as part of a multicenter trial: Heparin Infusion Prior to Stenting. Planar IVUS measurements 1 mm apart were obtained throughout the stent and over a length of 10 mm proximal and distal to the stent at index and follow-up. Of the 179 patients enrolled, 140 returned for repeat angiography and IVUS at 6.4 ± 1.9 months and had IVUS images adequate for analysis. Patients had 1.2 ± 0.6 Palmaz-Schatz stents per vessel. There was a wide individual variation of intimal hyperplasia distribution within the stent and no mean predilection for any location. At 6 months, intimal hyperplasia occupied 29.3 ± 16.2% of the stent volume on average. Lumen loss within 2 mm of the stent edge was due primarily to intimal proliferation. Beyond 2 mm, negative remodeling contributed more to lumen loss. Gender, age, vessel location, index plaque burden, hypercholesterolemia, diabetes, and tobacco did not predict luminal narrowing at the stent edges, but diabetes, unstable angina at presentation, and lesion length were predictive of in-stent intimal hyperplasia. In a non-radiation stent population, 29% of the stent volume is filled with intimal hyperplasia at 6 months. Lumen loss at the stent edge is due primarily to intimal proliferation.

UR - http://www.scopus.com/inward/record.url?scp=0035422744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035422744&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(01)01635-6

DO - 10.1016/S0002-9149(01)01635-6

M3 - Article

C2 - 11472702

AN - SCOPUS:0035422744

VL - 88

SP - 248

EP - 252

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -